Overview

* Paysign Q2 2025 revenue grows 33.1%, beating analyst expectations

* Adjusted EBITDA for Q2 2025 beats consensus, rising 101.8% yr/yr

* Company added 123 net plasma centers, exiting quarter with 607 centers

Outlook

* Paysign ( PAYS ) revises full-year 2025 revenue to $76.5 mln-$78.5 mln

* Company expects Q3 2025 revenue between $19.5 mln and $20.5 mln

* Paysign ( PAYS ) sees plasma revenue flat, pharma revenue up 145% in 2025

* Company expects Q3 2025 gross profit margin around 59%

Result Drivers

* PHARMA GROWTH - Pharma patient affordability revenue surged 189.9% due to new programs and increased claims processing

* PLASMA CHALLENGES - Plasma revenue declined 4.7% amid industry oversupply, despite adding 123 net plasma centers

* COST INCREASES - Costs rose due to growth in pharma programs, wage inflation, and onboarding of new plasma centers

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $19.08 $18.70

Revenue mln mln (5

Analysts

)

Q2 EPS $0.02

Q2 Net $1.39

Income mln

Q2 Beat $4.51 $4.39

Adjusted mln mln (5

EBITDA Analysts

)

Q2 Gross 61.6%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the business support services peer group is "buy"

* Wall Street's median 12-month price target for Paysign Inc ( PAYS ) is $8.00, about 10.5% above its August 4 closing price of $7.16

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)